Abstract
Background
Optic neuropathy is a disorder characterised by dysfunction or destruction of the optic nerve tissues. Acquired causes include interruption in the blood supply, nutritional deficiency, compression by a tumour or aneurysm, trauma, and toxic types (Ambizas and Patel In US Pharm 36(4):HS2–HS6, 1). Drug-induced optic neuropathy is of the toxic type and can be defined as a clinical syndrome characterised by papillomacular bundle damage, central, or cecocentral scotoma, and reduced colour vision (Ambizas and Patel In US Pharm 36(4):HS2–HS6, 2011; Sharma and Sharma In Indian J Ophthalmol 59(2):137–141, 2).
Aim
To report a case unilateral optic neuritis, secondary to the use of the antiandrogen, cyproterone acetate.
Case report
A 21-year-old female presented with a 4-day history of right brow pain exacerbated by eye movement, and blurring of the right temporal field of vision. She had been taking desogestrel 75 mg and cyproterone acetate 50 mg for the previous 2 months for hormone imbalance. Unaided right visual acuity measured 6/9 and unaided left visual acuity measured 6/6 on Snellen chart. Right red desaturation was present. Goldmann perimetry showed a right enlarged blind spot with predominantly temporal visual field loss. Visually evoked potential (VEP) testing of the right eye showed slightly increased latency, but normal amplitude. Three weeks after discontinuation of the antiandrogen therapy, her symptoms resolved. Repeat Goldmann visual fields showed expansion.
Conclusion
Known side-effects of cyproterone acetate include retinal vascular disorder and retinal vein thrombosis, but an association with optic neuritis had not been described to date. There was a temporal relationship between cessation of the medication and improvement in visual symptoms. This implies that discontinuation of the offending drug constitutes the basis of treatment in drug-induced optic neuropathy.
Similar content being viewed by others
References
Ambizas EM, Patel PN (2011) Drug-induced optic neuropathy. US Pharm 36(4):HS2–HS6
Sharma P, Sharma R (2011) Toxic optic neuropathy. Indian J Ophthalmol 59(2):137–141
Al-Dhibi H, Chaudhry IA, Al-Saati A, Shamsi FA (2007) Efficacy of intravitreal triamcinolone for macular oedema due to CRVO after anti-androgen therapy for hirsutism in a young monocular female. Br J Ophthalmol 91(11):1564–1565
Markus H, Polkey M, Harrison M (1992) Visual loss and optic atrophy associated with cyproterone acetate. BMJ 305(6846):159
Aroudj S, Baratta A (2012) Paraphilia, chemical castration and optic neuropathy: a case report. Ann Medico–Psychol 170:579–581 (no. 8)
Bove et al (2014) Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler 20(12):1584–1592
Maggio et al (2005) The relationship between testosterone and molecular markers of inflammation in older men. J Endocrinol Invest 28:116–119
Trufyn JJ et al. ( 2013) The role of oral contraceptives in optic neuritis: the story behind the study, initial experiences, and lessons learned. A thesis submitted to the faculty of graduate studies in partial fulfillment of the requirements for the degree of master of science. Department of neuroscience, Calgary, Alberta
Confavreux C, Aimard G, Devic M (1980) Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103:281–300
Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernán MA (2005) Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol 62:1362–1365
Bove R et al (2016) Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler 22(7):935–943
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Rights and permissions
About this article
Cite this article
Ní Mhéalóid, Á., Cunniffe, G. Optic neuritis secondary to antiandrogen therapy. Ir J Med Sci 186, 565–570 (2017). https://doi.org/10.1007/s11845-016-1544-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-016-1544-1